Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Frankfurt - Delayed Quote EUR

Veru Inc. (FMW.F)

Compare
0.4898
-0.0432
(-8.11%)
As of 8:08:23 AM GMT+1. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
9/30/2024
9/30/2023
9/30/2022
9/30/2021
Total Revenue
16,886.4190
16,886.4190
16,296.9580
39,354.3520
61,259.5280
Cost of Revenue
--
11,032.4420
8,731.0300
8,762.9640
13,332.3050
Gross Profit
--
5,853.9770
7,565.9280
30,591.3880
47,927.2230
Operating Expense
46,626.0270
43,992.2820
103,171.7670
114,079.5460
53,364.7240
Operating Income
-40,772.0500
-38,138.3050
-95,605.8390
-83,488.1580
-5,437.5010
Net Non Operating Interest Income Expense
--
-607.4700
-2,427.0410
-4,368.7980
-4,886.0540
Other Income Expense
10,160.6750
1,669.4500
5,360.3940
4,052.7350
14,588.7910
Pretax Income
-31,218.8450
-37,076.3250
-92,672.4860
-83,804.2210
4,265.2360
Tax Provision
--
725.1010
480.2060
236.3970
-3,129.1380
Net Income Common Stockholders
-38,470.7920
-37,801.4260
-93,152.6920
-84,040.6180
7,394.3740
Diluted NI Available to Com Stockholders
-38,470.7920
-37,801.4260
-93,152.6920
-84,040.6180
7,394.3740
Basic EPS
-0.26
-0.28
-1.10
-1.05
0.10
Diluted EPS
-0.26
-0.28
-1.10
-1.05
0.09
Basic Average Shares
146,320.5100
134,875.0160
84,973.3820
80,122.5260
76,272.8530
Diluted Average Shares
146,320.5100
134,875.0160
84,973.3820
80,122.5260
83,802.4200
Total Operating Income as Reported
-39,772.2980
-36,915.3970
-93,782.2160
-83,488.1580
12,972.6570
Total Expenses
57,658.4690
55,024.7240
111,902.7970
122,842.5100
66,697.0290
Net Income from Continuing & Discontinued Operation
-38,470.7920
-37,801.4260
-93,152.6920
-84,040.6180
7,394.3740
Normalized Income
-41,184.2190
-38,439.6125
-96,934.1242
-86,850.6480
-3,366.6713
Interest Expense
--
607.4700
2,427.0410
4,368.7980
4,851.7530
Net Interest Income
--
-607.4700
-2,427.0410
-4,368.7980
-4,886.0540
EBIT
-39,102.6000
-36,468.8550
-90,245.4450
-79,435.4230
9,116.9890
EBITDA
-38,841.6820
-36,200.6780
-89,975.5710
-79,225.8280
9,328.3830
Reconciled Cost of Revenue
--
11,032.4420
8,731.0300
8,762.9640
13,332.3050
Reconciled Depreciation
260.9180
268.1770
269.8740
209.5950
211.3940
Net Income from Continuing Operation Net Minority Interest
-31,943.9460
-37,801.4260
-93,152.6920
-84,040.6180
7,394.3740
Total Unusual Items Excluding Goodwill
9,240.2730
807.8310
4,786.6230
3,557
14,741.1580
Total Unusual Items
9,240.2730
807.8310
4,786.6230
3,557
14,741.1580
Normalized EBITDA
-48,081.9550
-37,008.5090
-94,762.1940
-82,782.8280
-5,412.7750
Tax Rate for Calcs
--
0.0002
0.0002
0.0002
0.0003
Tax Effect of Unusual Items
--
169.6445
1,005.1908
746.9700
3,980.1127
9/30/2021 - 3/5/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ENZN Enzon Pharmaceuticals, Inc.
0.1000
+1.01%
 
KPRX Kiora Pharmaceuticals, Inc.
3.3600
-0.59%
 
GLSI Greenwich LifeSciences, Inc.
11.57
-2.36%
 
COCP Cocrystal Pharma, Inc.
1.7850
-2.46%
 
TENX Tenax Therapeutics, Inc.
5.90
-5.90%
 
PALI Palisade Bio, Inc.
0.8899
-5.98%
 
PULM Pulmatrix, Inc.
8.28
+5.75%
 
CYCN Cyclerion Therapeutics, Inc.
2.6900
+0.75%
 
QNRX Quoin Pharmaceuticals, Ltd.
0.3100
-1.15%
 
SRRK Scholar Rock Holding Corporation
36.35
-2.18%